Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions.
In the company’s own words · 10-K filed Dec 4, 2025 · SEC EDGAR
Business segments
Q1 2026 · $144.8MThe company’s own SEC segment disclosure.
- US$83.0M57%
- Europe$25.9M18%
- CN$16.9M12%
- GB$10.4M7%
- Asia Pacific Excluding China$7.5M5%
- Other$1.1M1%
Azenta, Inc. (AZTA) reported revenue of $145M in Q2 2026 (quarter ended March 31, 2026), up 1.0% from the same quarter a year earlier. That came with a gross margin of 43% and net loss of $161M. For the full year FY2025, revenue was $594M (+3.6% year on year) and net income −$56M. Its largest region in 2026-Q1 was US at $83M, 57% of the disclosed total, just ahead of Europe at 18%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #24 of 27 by Smart Score